The purpose of the invention is to develop and provide a novel therapeutic agent for hepatitis B that differs from the conventional therapeutic agent for hepatitis B in the mechanism of action, or target of interest.

Provided is an inhibitor of hepatitis B virus replication consisting of a spike region in the core protein of a hepatitis B virus, or an expression vector containing a nucleic acid encoding the same.

The purpose of the invention is to develop and provide a novel therapeutic agent for hepatitis B that differs from the conventional therapeutic agent for hepatitis B in the mechanism of action, or target of interest.

Provided is an inhibitor of hepatitis B virus replication consisting of a spike region in the core protein of a hepatitis B virus, or an expression vector containing a nucleic acid encoding the same.

The present disclosure provides vaccine compositions and methods for inducing a systemic immune response and a mucosal immune response, wherein the vaccine compositions comprise an antigen and a hepatitis B core virus-like particle (HBc VLP) as adjuvant. The vaccine compositions are suitable for administration to the mucosa surface of subject, and are effective in eliciting a protective immune response against infection.

The present disclosure provides vaccine compositions and methods for inducing a systemic immune response and a mucosal immune response, wherein the vaccine compositions comprise an antigen and a hepatitis B core virus-like particle (HBc VLP) as adjuvant. The vaccine compositions are suitable for administration to the mucosa surface of subject, and are effective in eliciting a protective immune response against infection.

The present disclosure provides vaccine compositions and methods for inducing a systemic immune response and a mucosal immune response, wherein the vaccine compositions include an antigen and a hepatitis B core virus-like particle (HBc VLP) as an adjuvant. The vaccine compositions are suitable for administration to the mucosal surface of a subject, and are effective in eliciting a protective immune response against infection.

The present disclosure provides vaccine compositions and methods for inducing a systemic immune response and a mucosal immune response, wherein the vaccine compositions include an antigen and a hepatitis B core virus-like particle (HBc VLP) as an adjuvant. The vaccine compositions are suitable for administration to the mucosal surface of a subject, and are effective in eliciting a protective immune response against infection.

Chimeric genes, compositions of chimeric genes, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include chimeric genes encoding hepatitis D antigen (HDAg) protein in combination with one or more self-cleavage 2A polypeptides and a preS1 polypeptide. In certain embodiments the self-cleavage polypeptide is P2A.

Chimeric genes, compositions of chimeric genes, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include chimeric genes encoding hepatitis D antigen (HDAg) protein in combination with one or more self-cleavage 2A polypeptides and a preS1 polypeptide. In certain embodiments the self-cleavage polypeptide is P2A.

A hepatitis B vaccine comprising a surface antigen particle that has only hepatitis B virus L protein or a variant thereof assembling on a lipid membrane to form the particle.

The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D virus (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.